AffyXell, Avacta’s joint venture with Daewoong Pharmaceutical, expands its manufacturing partnership with GenScript ProBio for cell therapies

AffyXell, Avacta’s joint venture with Daewoong Pharmaceutical, expands its manufacturing partnership with GenScript ProBio for cell therapies
Genflow (LSE: GENF), a UK-based biotechnology company focused on longevity and the development of therapies to counteract the effects of ageing and diseases associated with advanced age, is pleased to
Focused on the on development and commercialisation of Lyme disease lateral flow self-test
Update on POLB 001 Clinical Development
Key considerations document for developing and manufacturing challenge agents published
Poolbeg to engage with key international stakeholders at congress as it develops an intramuscular Melioidosis vaccine candidate
Avacta establishes new Therapeutics headquarters at Scale Space, Imperial College White City Campus
Placing of 50,000,000 New Ordinary Shares and Warrants
First site study awarded offering new site services since facilities expansion
Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, notes market
Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that